机译:早期全身癌症的诊断病理:单一播种癌细胞中的ERBB2 ERBB2基因扩增决定了可操作食管癌中的患者存活
Division of Personalized Tumor TherapyFraunhofer Institute for Toxicology and Experimental Medicine;
Chair of Experimental Medicine and Therapy ResearchUniversity of RegensburgGermany;
Chair of Experimental Medicine and Therapy ResearchUniversity of RegensburgGermany;
Chair of Experimental Medicine and Therapy ResearchUniversity of RegensburgGermany;
Department of General Visceral and Pediatric SurgeryUniversity Hospital Duesseldorf Heinrich;
Department of General Visceral and Pediatric SurgeryUniversity Hospital Duesseldorf Heinrich;
Department of GynecologyCaritas‐Hospital St. Josef University of RegensburgGermany;
Department of General Visceral and Pediatric SurgeryUniversity Hospital Duesseldorf Heinrich;
Department of General Visceral and Thoracic SurgeryUniversity Hospital Hamburg‐EppendorfHamburg;
Division of Personalized Tumor TherapyFraunhofer Institute for Toxicology and Experimental Medicine;
Department of General Visceral and Pediatric SurgeryUniversity Hospital Duesseldorf Heinrich;
Division of Personalized Tumor TherapyFraunhofer Institute for Toxicology and Experimental Medicine;
metastasis; single disseminated cancer cells; esophageal cancer; ERBB2 gene amplification; quantitative PCR;
机译:早期全身癌症的诊断病理:单一播种癌细胞中的ERBB2 ERBB2基因扩增决定了可操作食管癌中的患者存活
机译:大型亚洲癌症患者队列中无细胞DNA中
机译:可手术乳腺癌患者循环和弥散性肿瘤细胞HER2基因扩增的不一致
机译:在胃癌细胞中解开ErbB2糖基化签名
机译:人乳腺癌细胞中ErbB2不依赖网格蛋白的内吞作用。
机译:大型亚洲癌症患者队列中无细胞DNA中ERBB2(HER2)基因扩增事件的检测以及对抗HER2试剂的反应
机译:早期全身癌症的诊断病理:单播种癌细胞中的ERBB2戈斯扩增决定了可操作食管癌中的患者存活